Cover Image
市場調查報告書

腹膜炎:開發中產品分析

Peritonitis - Pipeline Review, H1 2017

出版商 Global Markets Direct 商品編碼 360906
出版日期 內容資訊 英文 45 Pages
訂單完成後即時交付
價格
Back to Top
腹膜炎:開發中產品分析 Peritonitis - Pipeline Review, H1 2017
出版日期: 2017年05月23日 內容資訊: 英文 45 Pages
簡介

腹膜炎,是腹膜發炎,有2種腹膜炎。 自然細菌性腹膜炎(SBP),是由腹水感染。二次腹膜炎,通常是由消化管擴散的感染疾病。症候為腹部膨脹,噁心及嘔吐,腹瀉,疲勞,發熱發冷等。使用抗生素治療。

本報告提供腹膜炎的治療藥的開發情形相關調查分析,開發中產品的概要,治療藥的開發合作主要企業及藥物簡介,最新的開發平台趨勢等資訊。

簡介

  • 調查範圍

腹膜炎概要

治療藥的開發

  • 開發中產品的概要
  • 各企業的開發平台
  • 在大學/研究機關開發的開發平台
  • 企業開發中的產品
  • 在大學/研究機關開發中的產品

治療藥的評估

  • 各標的
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

開發腹膜炎治療藥的企業

  • Adenium Biotech ApS
  • Allergan Plc
  • GlaxoSmithKline Plc
  • Oncodesign SA
  • SynAct Pharma AB

藥物簡介

腹膜炎:暫停中的計劃

腹膜炎:產品開發里程碑

  • 主要消息和新聞稿

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC9315IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Peritonitis - Pipeline Review, H1 2017, provides an overview of the Peritonitis (Gastrointestinal) pipeline landscape.

Peritonitis is inflammation of the peritoneum. There are two types of peritonitis. Spontaneous bacterial peritonitis (SBP) is the result of an infection of the fluid in peritoneal cavity. Secondary peritonitis is usually due to an infection that has spread from digestive tract. Symptoms include abdominal bloating, nausea and vomiting, diarrhea, fatigue, fever and chills. Treatment includes antibiotics.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Peritonitis - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Peritonitis (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Peritonitis (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Peritonitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I and Preclinical stages are 1, 1 and 7 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Peritonitis (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Peritonitis (Gastrointestinal).
  • The pipeline guide reviews pipeline therapeutics for Peritonitis (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Peritonitis (Gastrointestinal) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Peritonitis (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Peritonitis (Gastrointestinal)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Peritonitis (Gastrointestinal).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Peritonitis (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Peritonitis - Overview
    • Peritonitis - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Peritonitis - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Peritonitis - Companies Involved in Therapeutics Development
    • Adenium Biotech ApS
    • Allergan Plc
    • GlaxoSmithKline Plc
    • Oncodesign SA
    • SynAct Pharma AB
    • Peritonitis - Drug Profiles
    • AA-139 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AcPepA - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AP-1189 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • cenicriviroc mesylate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • molgramostim - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • R-10001 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit Nitric Oxide Synthase for Rheumatism, Arthritis and Peritonitis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit RIP2 for Polyarthritis, Gastrointestinal Disorders and Rheumatoid Arthritis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SRT-3025 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Stem Cell Therapy for Inflammation, Corneal Injury and Peritonitis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Peritonitis - Dormant Projects
  • Peritonitis - Product Development Milestones
    • Featured News & Press Releases
      • Jun 19, 2016: Reponex Pharmaceuticals: The Danish Medicines Agency has approved the clinical trial protocol for the peritonitis project
      • Mar 20, 2015: Tobira Therapeutics Highlights Presentations at the AASLD's Industry Colloquium for Novel Targets and Therapies in Liver Disease
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Peritonitis, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Products under Development by Companies, H1 2017
  • Products under Development by Universities/Institutes, H1 2017
  • Number of Products by Stage and Target, H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017
  • Number of Products by Stage and Route of Administration, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
  • Peritonitis - Pipeline by Adenium Biotech ApS, H1 2017
  • Peritonitis - Pipeline by Allergan Plc, H1 2017
  • Peritonitis - Pipeline by GlaxoSmithKline Plc, H1 2017
  • Peritonitis - Pipeline by Oncodesign SA, H1 2017
  • Peritonitis - Pipeline by SynAct Pharma AB, H1 2017
  • Peritonitis - Dormant Projects, H1 2017

List of Figures

  • Number of Products under Development for Peritonitis, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products by Top 10 Targets, H1 2017
  • Number of Products by Stage and Top 10 Targets, H1 2017
  • Number of Products by Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Routes of Administration, H1 2017
  • Number of Products by Stage and Routes of Administration, H1 2017
  • Number of Products by Molecule Types, H1 2017
  • Number of Products by Stage and Molecule Types, H1 2017
Back to Top